Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹4,09,339 Cr
P/E Ratio
35.8
P/B Ratio
5.68
Industry P/E
35.8
Debt to Equity
0.04
ROE
16.13 %
ROCE
17.6 %
Div. Yield
0.79 %
Book Value
300.22
EPS
49.15
CFO
₹64,291.40 Cr
EBITDA
₹87,158.11 Cr
Net Profit
₹52,845.20 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
| -9.65 | 0.22 | -5.83 | 10.08 | 24.22 | 35.83 | 5.17 |
|
BSE Sensex
| -5.21 | -2.33 | -9.27 | 2.10 | 9.29 | 18.76 | 10.06 |
|
BSE Healthcare
| -12.03 | -0.38 | -9.99 | 17.17 | 18.21 | 26.68 | 8.93 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
| 49.68 | 25.77 | 18.41 | 41.84 | 36.39 | -0.23 | -25.01 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,492.60 | 1,20,580.95 | 24.17 | 18.12 | |
| 1,150.70 | 95,999.92 | 17.87 | 18.21 | |
| 2,170.95 | 89,616.18 | 43.9 | 20.49 | |
| 3,066.35 | 1,03,569.38 | 55.62 | 25.93 |
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations... in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and anti retro viral medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India. Read more
Incorporated
1993
Chairman
Dilip S Shanghvi
Managing Director
Dilip S Shanghvi
Group
Sun Pharma
Headquarters
Vadodara, Gujarat
Website
Looking for more details about Sun Pharmaceutical Industries Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sun Pharmaceutical Industries Ltd stood at ₹ 88,116 Cr as on 31-Dec-24
The share price of Sun Pharmaceutical Industries Ltd is ₹1,704.30 (NSE) and ₹1,706.05 (BSE) as of 17-Mar-2025 IST. Sun Pharmaceutical Industries Ltd has given a return of 24.22% in the last 3 years.
Sun Pharmaceutical Industries Ltd has a market capitalisation of ₹ 4,09,339 Cr as on 17-Mar-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Sun Pharmaceutical Industries Ltd is 5.68 times as on 17-Mar-2025, a 18% premium to its peers’ median range of 4.83 times.
The P/E ratio of Sun Pharmaceutical Industries Ltd is 35.80 times as on 17-Mar-2025, a 0% premium to its peers’ median range of 35.80 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sun Pharmaceutical Industries Ltd and enter the required number of quantities and click on buy to purchase the shares of Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and anti retro viral medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.
The promoters of Sun Pharmaceutical Industries Ltd are Shanghvi Finance Private Limited and Dilip.S.Shanghvi. They collectively own 49.9 per cent of the total equity. The chairman of the company is Dilip S Shanghvi
The promoters of Sun Pharmaceutical Industries Ltd have pledged 0.38% of the total equity as on Dec-24.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
1,17,803
|
|
|
1,03,974
|
|
|
95,530
|
|
|
94,527
|
| Sun Pharmaceutical Industries Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
17.76
|
|
Operating margin(%)
|
23.06
|
|
Net Margin(%)
|
21.39
|
|
Dividend yield(%)
|
0.79
|
Yes, TTM profit after tax of Sun Pharmaceutical Industries Ltd was ₹11,434 Cr.
₹20.85
(
